Acquired Company
Ironwood acquired VectivBio on 12/12/2023 in an all-cash merger at $17.00 per share with aggregate consideration of approximately $1.2 billion.
VectivBio Holding AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of treatments for rare conditions. The company is headquartered in Basel, Switzerland. Show more
AESCHENVORSTADT 36, BASEL, SWITZERLAND, 4051, USA
Market Cap
1.058B
52 Wk Range
$0.00 - $0.00
Previous Close
$16.85
Open
$16.85
Volume
N/A
Day Range
$16.85 - $16.85
Enterprise Value
0.00
Cash
221.4M
Avg Qtr Burn
N/A
Insider Ownership
4.50%
Institutional Own.
83.80%
Qtr Updated
03/31/23
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|